STATUTORY INSTRUMENTS

2019 No. 775

The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

PART 3

Amendment of Part 3 (manufacture and distribution of medicinal products and active substances)

Amendment of regulation 45F (provision of information)

41. In regulation 45F(1) [M1] for sub-paragraph (b) substitute—

[[F1]"(b) in the case of a broker in—

(i) Great Britain, either—

(aa) the UK marketing authorisation holder, or

(bb) where applicable, the holder of the licence or authorisation granted by an appropriate authority responsible for the licensing of medicinal products in an approved country for import, or

(ii) Northern Ireland, either—

(aa) the UK marketing authorisation holder, or

(bb) where applicable, the EU marketing authorisation holder,"**]**.

Textual Amendments

F1 Words in reg. 41 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, **Sch. 2 para. 30**

Commencement Information

I1 Reg. 41 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see reg. 1

Marginal Citations

M1 Regulation 45F was inserted by S.I. 2013/1855.

Changes to legislation:
There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 41.